Belsomra costs roughly $474 for a 30-day supply without insurance, while generic zolpidem (the active ingredient in Ambien) runs about $12 to $13 for 100 tablets. That’s not a typo. The price gap between Belsomra and older sleep medications is enormous, and several factors explain why.
A Different Kind of Sleep Drug
Most sleep medications, like zolpidem, zaleplon, and eszopiclone, work by enhancing the activity of GABA, a chemical that broadly sedates the brain. They’re effective but come with well-known downsides: dependence, rebound insomnia, and next-day grogginess. These drugs have been around long enough that multiple generic versions exist, which is the single biggest reason they’re cheap.
Belsomra (suvorexant) works through a completely different mechanism. Instead of sedating the brain, it blocks orexin receptors, the signaling system your brain uses to maintain wakefulness. By switching off the wake signal rather than forcing sleep, Belsomra promotes sleep without the same rebound insomnia or dependence risk seen with older drugs. Developing a first-in-class drug with a novel mechanism requires years of research and costly clinical trials, and Merck prices Belsomra to recoup that investment while it still holds patent protection.
No Generic Competition Yet
The most important reason Belsomra is expensive is straightforward: there is no generic version. When a drug is under patent, the manufacturer sets the price without competitive pressure. Generic zolpidem became dirt cheap precisely because dozens of manufacturers can produce it. Until Belsomra’s patents expire and generic suvorexant enters the market, Merck faces no price competition from identical products.
Even within its own drug class, Belsomra isn’t uniquely overpriced. Quviviq (daridorexant), a newer orexin blocker, costs about $520 for a 30-day supply. These brand-name orexin antagonists are all priced in the same ballpark because none of them face generic competition.
Insurance Hurdles Add to the Problem
If you have insurance, you might assume your plan will absorb most of the cost. In practice, many insurers make Belsomra difficult to access. Health plans commonly require “step therapy,” meaning you have to try and fail cheaper medications first before they’ll cover Belsomra. A typical prior authorization form asks whether you’ve already tried zolpidem extended-release or eszopiclone, whether you’ve attempted non-drug approaches like cognitive behavioral therapy for insomnia, and whether those options were inadequate.
If your insurer does cover Belsomra, it’s usually placed on a higher formulary tier with a significant copay. If your prior authorization is denied, or if your plan doesn’t cover it at all, you’re looking at the full retail price. This is the scenario where the $474 sticker shock hits hardest.
What You Can Do About the Cost
Merck runs a patient assistance program through MerckHelps that provides Belsomra free of charge to people who qualify. The program is designed for uninsured individuals who can’t afford their medication. Income limits are $63,840 or less for a single person, $86,560 for couples, and $132,000 for a family of four. A single application can cover up to one year of free medication, and you can reapply as many times as needed. If you have insurance but face financial hardship, you can request an exception.
Beyond the manufacturer program, it’s worth asking your doctor whether an older, generic sleep medication might work for your situation. For many people with insomnia, zolpidem or eszopiclone is effective and costs a fraction of what Belsomra does. The orexin-blocking mechanism offers real advantages for certain patients, particularly those concerned about dependence or who haven’t responded well to GABA-based drugs, but it’s not the only option.
Will It Ever Get Cheaper?
Belsomra’s price will drop significantly once generic suvorexant becomes available. Patent expiration timelines can shift due to legal challenges and extensions, but the pattern is predictable: once generics enter the market, prices typically fall 80% or more within a few years. Until then, the combination of patent exclusivity, a novel drug class, and limited insurance coverage keeps Belsomra firmly in the premium price category.